De Novo MET-amplified NSCLC treated with savolitinib achieved remarkable tumor regression: a case report and review of literature. Sheng J, Jiao J, Yan N, Pan H, et al. J Cancer Res Clin Oncol 2025;151:82.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sheng J, Jiao J, Yan N, Pan H, et al. De Novo MET-amplified NSCLC treated with savolitinib achieved remarkable tumor regression: a case report and review of literature. J Cancer Res Clin Oncol 2025;151:82.
PMID: 39948189